GlassScriptPhysician profile
Thomas A Spetalnick
NPI 1124114046
$7,134.99
in general payments reported to CMS, 2019-2025
28 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $451 · 2021: $217 · 2022: $1,683 · 2023: $831 · 2024: $1,290 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,039 · Entertainment: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.47 |
| Entertainment | $114.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $932.54 | 2019-2025 | Wavelight Ex500 Excimer Laser, Tryptyr, Wavelight Refractive Suite |
| Glaukos Corporation | $880.46 | 2022-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Photrexa |
| Abbvie INC. | $614.21 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $609.92 | 2022-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $550.69 | 2019-2022 | |
| Sight Sciences, INC. | $422.58 | 2021-2025 | Tearcare System |
| Coopervision INC. | $417.44 | 2022-2025 | Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $364.06 | 2022-2025 | Infuse |
| Dompe US, INC. | $290.52 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $250.17 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $249.43 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $229.59 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $203.41 | 2022-2023 | Acuvue |
| Oyster Point Pharma, INC. | $165.61 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.91 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $116.74 | 2022-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Iridex Corporation | $116.17 | 2023 | |
| Optos, INC. | $114.67 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Apellis Pharmaceuticals, INC. | $110.42 | 2024 | Syfovre |
| Lkc Technologies, INC. | $99.61 | 2025 | |
| Eyepoint US, INC. | $58.18 | 2020 | |
| Biotissue Holdings INC. | $57.36 | 2021-2025 | |
| Topcon Healthcare, INC. | $34.32 | 2020 | |
| Thea Pharma INC. | $23.77 | 2023 | |
| Horizon Therapeutics Plc | $20.58 | 2023 | Tepezza |
| Staar Surgical Company | $18.47 | 2019 | |
| Amgen INC. | $17.28 | 2024 | Tepezza |
| Allergan, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Spetalnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.